Amisulpride used for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic surgery

Amisulpride used for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic surgery: a prospective observational cohort study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600126491

Enrollment

Unknown

Registered

2026-06-10

Start date

2026-07-01

Completion date

Unknown

Last updated

2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Nausea and Vomiting

Interventions

Amisulpride:None

Eligibility

Sex/Gender

Female

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. 18 <= age <= 75; 2. 18 < BMI <= 30 kg/m^2; 3. Patients scheduled for gynecological laparoscopic surgery (such as: ovary, fallopian tube, uterus, and gynecological tumors, with an expected surgery duration of <= 3 hours); 4. Agree and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.ASA IV level or above; 2.Long-term use of opioid drugs or non-steroidal anti-inflammatory drugs; 3.Undergoing radiotherapy and chemotherapy; 4.Allergic to the medication used; 5.Pregnant or breastfeeding women; 6.Previously existing vestibular disorders or chronic dizziness, easily nauseated; 7.Recent use of antiemetic drugs or prophylactic antiemetic regimen (within 7 days before surgery); 8.Presence of neurological or psychiatric disorders, or cognitive impairment;

Design outcomes

Primary

Measure	Time frame
Complete remission (CR) rate within 24 hours after surgery;	—

Secondary

Measure	Time frame
PACU stay duration;	—

Countries

China

Contacts

Public ContactMin Yan

The second affiliated hospital of Zhejiang University school of medicine

zryanmin@zju.edu.cn+86 571 8778 3716

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026